GlaxoSmithKline forecast 2019 sales of its fast-growing shingles vaccine Shingrix to be “significantly” more than 1 billion pounds ($1.31 billion) on Wednesday as a drop in the British drugmaker’s free cash flow weighed on its shares.
Powered by WPeMatico